Clean Power Hydrogen signs MoU with Koch Modular for North America

CPH2 signed a non-binding 24-month MoU with Koch Modular to evaluate manufacturing and licensing of up to 100 MW of its membrane-free electrolyser technology for Mexico, the U.S. and Canada. The agreement frames technical, commercial and supply-chain assessments and could lead to a legally binding manufacturing/licensing deal; Koch Modular is a Koch Industries subsidiary. The MoU is non-binding and the parties will provide updates if they progress to a definitive agreement.

Analysis

A new pathway to localized, modular electrolyser manufacturing materially shifts where margin accrues in the hydrogen value chain: the bulk of near-term value will move to systems integrators and fabricators who can turnkey repeatable modules, not the IP owner alone. If modular plants scale to the low‑GW range within 3–5 years, equivalent manufacturing gross margins of $150–350k per MW could generate high-margin revenue for North American fabricators; that math makes licensing or contract-manufacturing deals disproportionately accretive to cashflow versus unit-sales of stacks.

Incumbent suppliers that sell membranes, balance‑of‑plant components, or large bespoke EPC services face a two‑pronged squeeze — price competition as modules commoditize and demand concentration toward localized supply chains favored by industrial buyers and procurement rules. Expect a wave of procurement re‑engineering: buyers will prioritize lifecycle cost metrics (kWh/kg, stack life hours) and localized CAPEX subsidies, which will accelerate winners who demonstrate 5–7 year total cost of ownership superiority.

Primary tail risks are technical durability and system‑level LCOH: a promising lab metric that fails to convert to >20,000 hour stack life or competitive AC→H2 efficiency will vaporize value for licensees and licensors alike. Near-term catalysts that can re‑rate the story are independently audited pilot data, binding offtake/manufacturing contracts with creditworthy counterparties, and government grants or domestic content certifications; absence of these within 12–18 months is a clear negative signal.

Contrarian take: the market is probably underweight the licensing leverage — a narrow IP moat combined with a low-capex manufacturing playbook can scale EBIT margins faster than unit sales imply — but it is equally vulnerable to execution failures. Tradeable watchpoints: verified stack durability, quoted system‑level CAPEX ($/kg H2), and a first paid order from a North American industrial buyer; each should be treated as make‑or‑break within 12–24 months.

Key Decisions for Investors

• Long selective exposure to the IP owner (CPH2) sized 0.5–1.5% of portfolio as a binary, high-volatility call on licensing upside; use 18–36 month horizon, set a hard stop at 60% drawdown and scale out on a 3x return.
• Long North American fabricators / equipment plays (Chart Industries, GTLS) for 12–24 months to capture modular manufacturing upside; use 6–12 month call spreads sized to <2% portfolio risk if pilot data confirms system economics — target asymmetric 2.5x+ payoff.
• Pair trade: long large-cap industrial gas/integrator exposure (Linde, LIN or Air Liquide, AI.PA) vs short pure-play European electrolyser OEMs (Nel, NEL.OL; ITM Power, ITM.L) for 12–24 months — rationale: incumbents capture downstream demand and service, OEMs risk margin compression; keep net exposure neutral and monitor firm-level orderbooks quarterly.
• Short small, speculative AIM hydrogen microcaps (other than the IP owner) trading on partnership headlines; limit position size to <0.5% portfolio and require public, auditable pilot metrics within 12 months or cut losses — these names tend to gap-down on failed scale proofs.